Gene Mutation Linked to Ulcerative Colitis Identified in Brisbane Family, Offering Hope for New Treatments
A multi-generational study of a Brisbane family has led to the discovery of a gene mutation linked to ulcerative colitis, a chronic inflammatory bowel disease. The breakthrough, published in Cellular and Molecular Gastroenterology and Hepatology, offers potential for the development of targeted therapies for the debilitating condition.
Understanding Ulcerative Colitis
Ulcerative colitis is a chronic disorder that causes inflammation and ulcers in the lining of the large intestine and rectum. Symptoms can include diarrhea, abdominal pain, weight loss and bleeding. More than 200 genes have been associated with inflammatory bowel disease, which includes both ulcerative colitis and Crohn’s disease. Crohn’s & Colitis Australia estimates that over 180,000 Australians live with Crohn’s disease or ulcerative colitis.
The Brisbane Family Study
Researchers from Mater Research, the University of Queensland, Monash University, Harvard Medical School, and Mass General Brigham in Boston studied five members of a Brisbane family – a grandmother, two of her children, and two grandchildren – all diagnosed with ulcerative colitis. Using advanced genomic sequencing, they identified a mutation in the OTUD3 gene as a potential cause of the condition.
OTUD3 Gene and Gut Integrity
Lead researcher Rabina Giri explained that the study was the first to link the OTUD3 gene to intestinal health. “We’ve known this gene plays a role in cancer biology, but now we’ve shown it’s essential for maintaining the integrity of the gut lining,” Dr. Giri said. “When it’s disrupted, inflammation follows.” The OTUD3 gene provides instructions for producing a protein crucial for maintaining the gut’s protective barrier. When this barrier fails, bacteria can invade, triggering chronic inflammation.
Wider Implications of the Discovery
Further analysis of data from UK and Finnish biobanks revealed the OTUD3 mutation was present in a “significant” number of other individuals with ulcerative colitis. Researchers also found OTUD3 dysfunction in patients without the specific mutation, suggesting other genetic or environmental factors may be involved. The team is investigating whether a high-sugar Western diet could trigger the disease in those genetically susceptible.
Potential for New Treatments
The discovery raises hopes for a new class of drugs to treat ulcerative colitis. Dr. Giri suggested that a drug capable of increasing protein expression related to OTUD3 could be a viable treatment strategy. The research team is exploring whether existing drugs used for other conditions could be repurposed for ulcerative colitis treatment.
Successful Early Diagnosis and Treatment
The research enabled the early diagnosis of ulcerative colitis in a young member of the Brisbane family, allowing for successful treatment with anti-tumor necrosis factor (TNF) drugs – medications that block inflammation – without the need for bowel removal. The patient has remained stable since 2021.
Expert Perspectives
Gastroenterologist Jake Begun, who leads Mater Research’s Inflammatory Bowel Disease Research Group, emphasized the importance of genetic research in understanding chronic diseases. Griffith University professor of pathology Albert Lam described the study findings as “significant,” highlighting the importance of the bowel barrier in ulcerative colitis.
Looking Ahead
Researchers are seeking additional funding to further investigate the potential of new therapies and to explore environmental factors contributing to inflammatory bowel disease. The study underscores the complex interplay between genetics, environment, and gut health in the development of ulcerative colitis, paving the way for more targeted and effective treatments.